AC
ARIA

Ascend Capital’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Ascend Capital’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-100,000
Closed -$639K – 170
2016
Q1 		$639K Buy
+100,000
New +$560K 0.06% 91
2015
Q2 		– Sell
-1,000,000
Closed -$8.24M – 212
2015
Q1 		$8.24M Buy
+1,000,000
New +$7.39M 0.28% 95

Other funds holding ARIA

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Ascend Capital's ARIA Position: Q2 2016 in Review

Ascend Capital sold out of Ariad Pharmaceuticals Inc (ARIA) in Q2 2016, closing a stake of 100,000 shares — an estimated $639K sold.

Ascend Capital first reported a position in ARIA in Q1 2015 and held it in 2 quarters. The position peaked at $8.24M in Q1 2015. 182 funds tracked by Wall St. Rank hold ARIA as of Q2 2016.

  • Ascend Capital reported no remaining Ariad Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Ascend Capital sold 100,000 Ariad Pharmaceuticals Inc shares in Q2 2016, an estimated $639K.
  • Ascend Capital first reported a position in Ariad Pharmaceuticals Inc in Q1 2015 and held it in 2 quarters.
  • Ascend Capital's Ariad Pharmaceuticals Inc position peaked at $8.24M in Q1 2015.
  • 182 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q2 2016.

Based on Ascend Capital's 13F filing for Q2 2016, filed 12 Aug 2016.